Send to

Choose Destination
J Neurooncol. 2009 Mar;92(1):99-105. doi: 10.1007/s11060-008-9741-z. Epub 2008 Nov 19.

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

Author information

Neuro-Oncology Branch, National Cancer Institute, 9030 Old Georgetown Road, Bethesda, MD 20892, USA.


Twenty-two patients with recurrent glioblastoma (GBM) were prospectively treated with everolimus and gefitinib, designed to test the combined inhibition of mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR) as part of a larger clinical trial. The primary endpoint was radiographic response rate. Secondary endpoints included progression-free survival and correlation of molecular profiles with treatment response. 36% of patients had stable disease and 14% a partial response; however, responses were not durable and only one patient was progression-free at six months. Radiographic changes were not well characterized by conventional response criteria, and implied differential effects of therapy within the tumor and/or antiangiogenic effects. EGFR and PTEN status did not clearly predict response to treatment.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center